You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands
SBC: OCATA THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): The ability to culture human embryonic stem cells generated a great deal of excitement about their vast potential for treating a variety of human diseases such as diabetes, heart disease, neurological, retinal and skin disorders to name a few. Unlike adult stem cells, embryonic stem cells have indefinite growth potential and the potential to develop into any t ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
VALIDATION OF FLUORESCENT DEOXYGLUCOSE (2-NBDG) IN TUMORS
SBC: 3GEN, LLC Topic: N/ADESCRIPTION (provided by applicant): A new fluorescent analogue of d-glucose, 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2- deoxyglucose (2-NBDG), was recently developed, but has not been characterized as a marker of glucose uptake in cancer cells. Validating this new tracer as a glucose analogue for optical imaging of superficial tumors may have a major impact on clinical and preclinical imag ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
High-Energy Imaging in Support of Radionuclide Therapy
SBC: ALPHAMED, INC Topic: N/ADESCRIPTION (provided by applicant): The overall goal of this project is to design and build cameras that can efficiently detect and image isotopes that have gamma rays with energies that are typically beyond those effectively accessible with conventional cameras. There are no nuclear medicine clinical cameras, today, that combine high efficiency with the ability to image high-energy gamma rays. ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Parallel DNA Assembling on MicroChip
SBC: ATACTIC TECHNOLOGIES, INC. Topic: N/ADESCRIPTION (provided by applicant): The increasing use of DNA as a molecular tool has ushered the technology of de novo synthesis of DNA back to the center stage of modern biology. We propose the development of a robust, ultra high-throughput (UHT) technology capable of genome-scale production of high fidelity synthetic DNA at about one percent of the cost and time of the current technologies. Ou ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
IMAGE-GUIDED ROBOTICALLY-POSITIONED TMS SYSTEM
SBC: CEREBRAL MAGNETICS, LLC Topic: N/ADESCRIPTION (provided by applicant): Interest in transcranial magnetic stimulation (IMS) has grown rapidly since its introduction in 1985, with clinicians and researchers worldwide now using IMS. Promising clinical applications include pre-surgical language mapping, and treatment of depression, Parkinson's disease, and Schizophrenia. Promising research applications include reversible-lesion mappin ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health